نتایج جستجو برای: anaplastic lymphoma kinase

تعداد نتایج: 333698  

2017
Yoshinobu Maeda Hisakazu Nishimori Isao Yoshida Yasushi Hiramatsu Masatoshi Uno Yasufumi Masaki Kazutaka Sunami Taro Masunari Yuichiro Nawa Hiromichi Yamane Hiroshi Gomyo Tsutomu Takahashi Tomofumi Yano Keitaro Matsuo Koichi Ohshima Shigeo Nakamura Tadashi Yoshino Mitsune Tanimoto

The standard CHOP therapy for peripheral T-cell lymphoma has resulted in unsatisfactory outcomes and it is still not clear what is the optimal front-line therapy. We conducted a multicenter phase II study of dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone (EPOCH) for untreated peripheral T-cell lymphoma patients. In this prospective study, 41 patients ...

2016
Andrea M Malone Lorna Storey Owen P Smith

Anaplastic large cell lymphoma (ALCL) is an uncommon form of non-Hodgkin lymphoma in younger patients, accounting for less than 15% of cases. It is exceedingly rare in infants, with a median age at diagnosis of 12 years. Various treatment strategies have been studied in pediatric ALCL, however the long-term event free survival is approximately 70% regardless of treatment approach. We present th...

Journal: :Blood 1995
J R Downing S A Shurtleff M Zielenska A M Curcio-Brint F G Behm D R Head J T Sandlund D D Weisenburger A E Kossakowska P Thorner

The t(2;5)(p23;q35) translocation was initially identified in cases of anaplastic large-cell lymphoma (ALCL) that expressed the Ki-1 (CD30) antigen. We have recently cloned this translocation and shown it to encode a chimeric product consisting of the N-terminal portion of a nonribosomal nucleolar phosphoprotein, nucleophosmin (NPM), from chromosome 5, fused to the kinase domain of a novel tran...

2017
Kanwardeep Singh Kwatra Preethi A. M. Paul Nalini Calton Joseph M. John James D. Cotelingam

BACKGROUND T-cell lymphomas with anaplastic morphology typically comprise of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL), ALK-negative ALCL (ALK- ALCL), and primary cutaneous ALCL (PC-ALCL). However, other entities such as diffuse large B-cell lymphoma, peripheral T-cell lymphoma, Hodgkin lymphoma, and undifferentiated carcinoma can also show similar anaplast...

2015
Giandomenico Roviello

In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib and ceritinib are two new tyrosine kinase inhibitors directed against the echinoderm microtubule-...

Journal: :Cancer letters 2010
E Ardini P Magnaghi P Orsini A Galvani M Menichincheri

The Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase first identified as the product of a gene rearrangement in Anaplastic Large Cell Lymphoma. ALK has subsequently been found to be rearranged, mutated, or amplified in a further series of tumours including neuroblastoma, and Non-Small Cell Lung Cancer. There is strong preclinical evidence that ALK is a driving force for oncogenesi...

Journal: :Cancer research 2008
Ultan McDermott A John Iafrate Nathanael S Gray Toshi Shioda Marie Classon Shyamala Maheswaran Wenjun Zhou Hwan Geun Choi Shannon L Smith Lori Dowell Lindsey E Ulkus Georgiana Kuhlmann Patricia Greninger James G Christensen Daniel A Haber Jeffrey Settleman

Selective kinase inhibitors have had a substantial impact on the field of medical oncology. Whereas these agents can elicit dramatic clinical responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion. We have established an automated platform for examining the sensitivity to various molecularly targeted inh...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید